SUMMIT, N.J., Dec 16, 2009 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG) announced the election of
Carrie S. Cox to the Company's Board of Directors. Ms. Cox is an
experienced corporate director with a distinguished career in global
healthcare. She has served as executive vice president and president of
Schering-Plough's Global Pharmaceutical Business, one of the largest and
most successful multi-national healthcare companies in the world. Before
joining Schering-Plough, Ms. Cox served as executive vice president and
president of Pharmacia Corporation's Global Prescription Business.
"We are delighted that a dynamic and experienced leader like Carrie Cox
is joining our Board of Directors," said Sol. J. Barer, Ph.D., Chairman
and Chief Executive Officer of Celgene Corporation." Her 25-plus years
of leadership and accomplishments in global healthcare will contribute
greatly to our objective to become a pre-eminent biopharmaceutical
company worldwide."
Ms. Cox is a member of the Board of Directors of Texas Instruments and
served on their audit and compensation committees, as well as recently
being appointed to the Board of Directors of Cardinal Health. She is
also a member of the Harvard School of Public Health's Health Policy and
Management Executive Council and a member of the Board of Overseers of
the University of Pennsylvania Museum of Archaeology and Anthropology.
FORTUNE magazine named Ms. Cox to its List of the "50 Most Powerful
Women in Business." She has been named "Healthcare Businesswoman of the
Year" by the Healthcare Businesswomen's Association and a "Woman of
Influence" by NJ Biz, New Jersey's leading business magazine. Ms.
Cox is a graduate of the Massachusetts College of Pharmacy.
About Celgene
Celgene Corporation, headquartered in Summit, New Jersey, is an
integrated global biopharmaceutical company engaged primarily in the
discovery, development and commercialization of innovative therapies for
the treatment of cancer and inflammatory diseases through gene and
protein regulation. For more information, please visit the Company's
website at www.celgene.com.
This release contains forward-looking statements which are subject to
known and unknown risks, delays, uncertainties and other factors not
under Celgene's control, which may cause actual results, performance or
achievements of Celgene to be materially different from the results,
performance or other expectations expressed or implied by these
forward-looking statements. These factors include results of current or
pending research and development activities, actions by the FDA and
other regulatory authorities, and other factors described in Celgene's
filings with the Securities and Exchange Commission such as its 10-K,
10-Q and 8-K reports.
SOURCE: Celgene Corporation
Celgene Corporation
David W. Gryska, 908-673-9059
Sr. Vice President and
Chief Financial Officer
or
Brian P. Gill, 908-673-9530
Vice President, Corporate Communications
